Perspectives and Future Directions
Part of the Pediatric Oncology book series (PEDIATRICO)
KeywordsClin Oncol Minimal Residual Disease Pediatric Oncology Group Study Chemotherapy Dose Intensity Favorable Prognostic Group
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- George RE, London WB, Maris JM, Cohn SL, Diller L, Brodeur GM, Castleberry RP, Look AT. Hyperdiploidy plus Non-amplified MYCN Confers a Favorable Prognostic Group in Children 12 to 18 Month of Age with Disseminated Neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol (in press)Google Scholar
- Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DM, Schmoldt J, Rademaker AW, Cohn SL (2002) Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 20:2284–2292CrossRefPubMedGoogle Scholar
- Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. N Engl J Med 341:1165–1173CrossRefPubMedGoogle Scholar
- Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Favorable prognosis for patients ages 12–18 month with stage 4 MYCN-nonamplified neuroblastoma. J Clin Oncol (in press)Google Scholar
© Springer-Verlag Berlin Heidelberg 2005